About Antidote
Antidote is a Healthcare company based in London (United Kingdom) founded in 2008 by Jessica Mann. Provider of search engine tool for patients to explore, understand and access clinical trials. Antidote has raised $52 million across 5 funding rounds from investors including LBO France, Merck Global Health Innovation Fund and Smedvig Capital. The company has 39 employees. Its chief executive, as recorded, is Nicole Anuszkiewicz Batiste. Its website antidote.me draws about 99 thousand monthly visits. Antidote offers products and services including Smart Match Search Engine and Precision Recruitment Services. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Clinical Trials. Its legal entity is ANTIDOTE TECHNOLOGIES LTD.
Company details
Antidote, earlier known as TrialReach, is a metasearch engine, helps patients to find and compare treatments in development and to connect them directly with the doctorsinvestigators carrying out the research. It also allows healthcare providers to put their patient data in their EMR into TrialReachs platform at scale, enabling groups of patients to be automatically matched to potentially suitable clinical trials.TrialReach is already working with leading health organizations, including the World Health Organization, and claims that three-quarters of the top twenty pharmaceutical companies are using its platform to support their clinical trials.
- Headquarters London, United Kingdom
- Employees 39
- Founders Jessica Mann
- SectorsHealthcare
- Phone•••• ••••
- Website antidote.me
- Social LinkedIn X Facebook YouTube
- Legal Name Antidote Technologies Ltd.
- Date of Incorporation 20 Apr, 2011
- Jurisdiction LONDON, ENGLAND
- Annual Revenue$10.68 M (USD)160as on Dec 31, 2021
- EBITDA-$2.08 M (USD)61as on Dec 31, 2021
- Total Equity Funding$52M (USD)
in 5 rounds
- Latest Funding Round$23.2M (USD), Series C
Jun 2021
- InvestorsLBO France
& 5 more
- Employee Count39
Products & Services of Antidote
Antidote offers a comprehensive portfolio of products and services, including Smart Match Search Engine and Precision Recruitment Services.
Tool that helps patients find appropriate clinical trials quickly.
Services for sponsors to fill clinical trials faster and efficiently.
Funding Insights of Antidote
Antidote has successfully raised a total of $52M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $23.2 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $52M
- Total Rounds 5
- Last Round Series C — $23.2M
- First Round $1.2M
(Oct 2011)
- Investors Count 6
All 5 funding rounds of Antidote with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2021 | $23.2M | Series C | – | LBO France | |
| Sep 2017 | $11M | Series B | – | Merck Global Health Innovation Fund | |
| Feb 2015 | $13.5M | Series B | – | Smedvig Capital | |
| May 2013 | $3.1M | Series A | – | Octopus Ventures | |
| Oct 2011 | $1.2M | Seed | – | Amadeus Capital | – |
6 investors in total: 6 institutional.
Investors in Antidote
Antidote has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include LBO France, Merck Global Health Innovation Fund and Smedvig Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments are made in France and the US. | lbofrance.com | Paris, France | ||
Corporate-backed venture capital is focused on the life science sector. | merckghifund.com | Kenilworth, United States | ||
Investment in private equity and venture capital since 1996. | smedvigcapital.com | |||
Venture capital investment and support for founders in technology and health sectors. | octopusventures.com | |||
Early-stage deep technology investments are made by Amadeus Capital. | amadeuscapital.com | London, United Kingdom | ||
Investment solutions are provided for tax planning and wealth management. | 2000 | octopusinvestments.com | London, United Kingdom |
Investor details for Antidote
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Antidote
15 people are tracked at Antidote (6 in leadership, 9 in team); the tracked headcount is 39.
| Name | Role | Group |
|---|---|---|
Jessica Mann | Co-Founder | Leadership |
Nicole Anuszkiewicz Batiste | Co-CEO | Leadership |
Samantha Veeck | Co-CEO | Leadership |
Adrianna Kruyt | Director of Business Development | Leadership |
Adele Andersson | Vice President Human Resources | Leadership |
Nicole Batiste | Co-ceo | Leadership |
Valerie Tufaro | Partnerships Associat | Team |
James Ciaramella | Frontend Developer | Team |
Krasimir Tsonev | Senior Engineer | Team |
Diana Castillo | Staff Software Engineer (Front-end) | Team |
Ronda Rajewski | Manager, Patient Experience And Workflow | Team |
Silvia Patricia Fuentevilla | Study Site and Patient Liaison Manager | Team |
Yvonne Taylor | Senior Clinial Site operations Manager | Team |
Ariane Mueller | Patient Liaison Manager | Team |
Neo Su | Senior Clinical Annotator | Team |
Complete people profiles for Antidote
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Antidote
3 dated milestones of Antidote across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Antidote is founded.
- Funding First funding round of $1.2M.
- Funding Latest funding round, Series C, of $23.2M.
Web traffic of Antidote
The website of Antidote (antidote.me) receives about 99.4K visits a month.
- Monthly visits99.4K
▲ 22% vs previous month
Websites whose visitors overlap most with Antidote. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
mrctcenter.org | mrctcenter.org | 100% | #1,323,515 | – | |
| flucamp.com | 98% | #490,754 | View details | ||
drugtargetreview.com | drugtargetreview.com | 84% | #387,873 | – | |
| labiotech.eu | 84% | 200.5K | #249,174 | View details | |
revivalresearch.org | revivalresearch.org | 84% | #779,398 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Antidote
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Antidote (Life Sciences Platforms & Tools) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | |||
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Antidote
Complete news archive for Antidote
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Antidote
Antidote was founded in 2008 and raised its 1st funding round 3 years after it was founded.
Antidote is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Nicole Anuszkiewicz Batiste is the CEO of Antidote, as recorded in our data.
Antidote is a funded company, having raised a total of $52M across 5 funding rounds to date. The company's 1st funding round was a Seed of $1.2M, raised on Oct 2011.
Antidote has 39 employees.
Annual revenue of Antidote is $10.68M as on Dec 31, 2021.
Antidote, earlier known as TrialReach, is a metasearch engine, helps patients to find and compare treatments in development and to connect them directly with the doctorsinvestigators carrying out the research. It also allows healthcare providers to put their patient data in their EMR into TrialReachs platform at scale, enabling groups of patients to be automatically matched to potentially suitable clinical trials.TrialReach is already working with leading health organizations, including the World Health Organization, and claims that three-quarters of the top twenty pharmaceutical companies are using its platform to support their clinical trials.
Antidote offers Smart Match Search Engine and Precision Recruitment Services.
Antidote has 6 investors. Key investors include LBO France, Merck Global Health Innovation Fund, Smedvig Capital, Octopus Ventures, and Amadeus Capital Partners.
Antidote operates through Antidote Technologies Ltd..